Predictors of overall survival based on the nutrition and morphofunctional assessment of patients with cancer: A prospective observational study
Nutrition in Clinical Practice · 2026-06 · 41 (3) · 756-767
DOI: 10.1002/ncp.70042 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Nutrition in Clinical Practice, online erschienen am 23.09.2025. Verfasst von Rosa M García-Moreno und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Clinical Nutrition and Dietetics Unit, Hospital Universitario La Paz, Madrid, Spain. Hauptthemen laut MEDLINE: Neoplasms, Nutrition Assessment, Nutritional Status, Malnutrition. Die Arbeit nennt 53 Literaturangaben. Gefördert von: None.
Abstract (Originalsprache)
Background
Disease‐related malnutrition (DRM) is a common complication of cancer and is associated with poor prognosis. Morphofunctional assessment has emerged as a new approach with high reliability for assessing body composition and nutrition status. This study performed a nutrition and morphofunctional evaluation in patients with cancer to identify predictors of overall survival.
Methods
This observational prospective study was conducted on patients with cancer who underwent nutrition assessment, which included morphofunctional techniques. The follow‐up period lasted 1 year after the initial evaluation, during which mortality rates were recorded. Survival analysis methods were used for statistical analysis.
Results
Among the 192 patients with cancer recruited, 24% died during the follow‐up. The reactance to height ratio (Xc/H) (hazard ratio [HR] 0.94, 95% confidence interval [CI] 0.90–0.98), the phase angle (PhA) (HR 0.52, 95% CI 0.34–0.78), the standardized PhA (SPhA) (HR 0.61, 95% CI 0.38–0.96), the body cell mass index (BCMI) (HR 0.83, 95% CI 0.71–0.97), the C‐reactive protein to prealbumin (CP) ratio (HR 1.89, 95% CI 1.04–3.46), the nonlimited physical capacity (HR 0.50, 95% CI 0.27–0.93), and the exercise practice (HR 0.12, 95% CI 0.02–0.88) were independent predictors of overall survival after adjusting for age, sex, and stage of cancer.
Conclusion
This research identifies several predictors of overall survival in cancer, including bioelectrical impedance analysis parameters (PhA, SPhA, Xc/H, and BCMI), as well as CP, nonlimited physical capacity, and exercise practice. Therefore, nutrition assessment, incorporating morphofunctional evaluation, can be benifical in patients with cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Clinical Nutrition and Dietetics Unit, Hospital Universitario La Paz, Madrid, Spain.
- Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain.
ORCID-Profile: Rosa M García-Moreno, Laura Mola Reyes, Isabella Mantellini González
Förderung
- None
Zitieren
APA
García-Moreno, R. M., Mola Reyes, L., Llaro Casas, M. G., Mantellini González, I., Rogic Valencia, S., López-Plaza, B., & Palma Milla, S. (2026). Predictors of overall survival based on the nutrition and morphofunctional assessment of patients with cancer: A prospective observational study. Nutrition in Clinical Practice, 41(3), 756-767. https://doi.org/10.1002/ncp.70042
Vancouver
García-Moreno RM, Mola Reyes L, Llaro Casas MG, Mantellini González I, Rogic Valencia S, López-Plaza B, et al. Predictors of overall survival based on the nutrition and morphofunctional assessment of patients with cancer: A prospective observational study. Nutrition in Clinical Practice. 2026;41(3):756-767. doi:10.1002/ncp.70042
BibTeX
@article{GarcaMoreno2026,
author = {García-Moreno, Rosa M and Mola Reyes, Laura and Llaro Casas, Mary Gaby and Mantellini González, Isabella and Rogic Valencia, Sime and López-Plaza, Bricia and Palma Milla, Samara},
title = {Predictors of overall survival based on the nutrition and morphofunctional assessment of patients with cancer: A prospective observational study},
journal = {Nutrition in Clinical Practice},
year = {2026},
volume = {41},
number = {3},
pages = {756--767},
doi = {10.1002/ncp.70042}
}
EUVIMED